한글목차

나노 의약품 시장은 2026년에 1,890억 달러 규모로 추정되며, 2033년까지 7,620억 달러에 달할 것으로 예측됩니다. 2026년부터 2033년까지 연평균 성장률(CAGR) 22.1%로 전망됩니다.

나노 의약품은 입자 크기가 1마이크로미터 미만인 새로운 의약품으로, 나노기술의 원리에 따라 작용하는 의약품입니다. 나노의약품은 치료용 화합물의 담체로서 또는 치료용 화합물 자체로서 약물전달에 널리 이용되고 있습니다. 나노 의약품은 특정 세포, 조직 또는 특정 장기를 표적으로 삼도록 설계되어 있습니다.

시장 역학

심혈관질환, 암, 감염성 질환의 유병률 증가는 나노 의약품 시장 성장을 이끄는 주요 요인입니다. 세계보건기구(WHO)의 2018년 9월 팩트시트에 따르면, 2017년에는 약 1,000만 명의 결핵 환자가 발생했고, 약 160만 명이 사망한 것으로 추정됩니다. 또한 거시적 차원의 의약품에 비해 나노의약품의 우위가 시장 성장을 촉진할 것으로 예상됩니다. 나노 의약품은 혈액뇌관문을 통과하여 뇌의 원격부위까지 도달할 수 있습니다. 또한, 화합물의 저용해성을 개선함으로써 그 특성을 더욱 향상시킬 수 있습니다.

본 조사의 주요 특징

• 이 보고서는 2017년을 기준 연도로 하여 예측 기간(2018-2026년)의 시장 규모와 연평균 성장률(CAGR%)을 제시하는 나노 의약품 시장에 대한 상세한 분석을 제공합니다.
• 또한, 다양한 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보도 제공합니다.
• 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 시장 입지, 유통 전략, 주요 개발, 전략, 미래 계획 등의 매개 변수를 기반으로 세계 나노 의약품 시장의 주요 업체를 프로파일링합니다.
• 이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 기술 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
• 이 세계 나노 의약품 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 나노의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 쉽게 의사결정을 내릴 수 있습니다.

목차

제1장 조사 목적과 가정

제2장 시장 범위

제3장 시장 역학, 규제, 동향 분석

제4장 세계의 나노 의약품 시장 : 캐리어 유형별, 2026-2033년

제5장 세계의 나노 의약품 시장 : 용도별, 2026-2033년

제6장 세계의 나노 의약품 시장 : 유통 채널별, 2026-2033년

제7장 세계의 나노 의약품 시장 : 지역별, 2026-2033년

제8장 경쟁 구도

제9장 섹션

영문목차

Nanopharmaceuticals Market is estimated to be valued at USD 1,89,000 Mn in 2026 and is expected to reach USD 7,62,000 Mn by 2033, growing at a compound annual growth rate (CAGR) of 22.1% from 2026 to 2033.

Nanopharmaceuticals are novel medicine with particle size less than 1 micron, which work on the principle of nanotechnology. Nanopharmaceuticals are widely used in drug delivery as a carrier for therapeutic compound or as a therapeutic compound. Nanopharmaceuticals are designed to target particular cells, tissue or a specific organ.

Market Dynamics

Increasing prevalence of cardiovascular diseases, cancer, and infectious diseases are major factors driving nanopharmaceuticals market growth. The World Health Organization, factsheet September 2018, estimated around 10 million cases of tuberculosis and around 1.6 million deaths from the disease in 2017. Moreover, advantages of nanopharmaceuticals over macroscopic level medicines is expected to boost the market growth. Nanopharmaceuticals can pass the blood brain barrier and can access the remote areas of brain as well as low solubility of the compound can be developed for enhancing its characteristics.

Key features of the study

• This report provides in-depth analysis of the nanopharmaceuticals market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
• It profiles key players in the global nanopharmaceuticals market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include, Abbott, GlaxoSmithKline and plc., Eli Lilly and Company, Astrazeneca plc., Novavax, Inc., Stryker Corporation, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Tanabe Pharma Corporation, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma Inc., Navidea Biopharmaceuticals, Inc., AbbVie Inc., AMAG Pharmaceuticals, Amgen Inc., Astellas Pharma Inc., Celgene Corporation, Gilead Sciences, Inc., JOHNSON & JOHNSON, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Hoffmann-La Roche AG, Sanofi S.A, Shire Plc., and Teva Pharmaceuticals Industries Limited.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics.
• The global nanopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the nanopharmaceuticals market

Market Segmentation

• By Carrier Type
  • Liposomes
  • Polymer
  • Nanocrystals
  • Inorganic
  • Protein
  • Others
• By Application
  • Oncology
  • Neurology
  • Anti-inflammatory
  • Anti-infective
  • Cardiovascular
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Key Players
  • Abbott
  • GlaxoSmithKline plc.
  • Eli Lilly and Company
  • Astrazeneca plc.
  • Novavax, Inc.
  • Stryker Corporation
  • OSI Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Samyang Biopharm
  • Mitsubishi Tanabe Pharma Corporation
  • Kaken Pharmaceutical
  • Selecta Biosciences
  • Par Pharmaceutical
  • Cerulean Pharma Inc.
  • Navidea Biopharmaceuticals, Inc.
  • AbbVie Inc.
  • AMAG Pharmaceuticals
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • JOHNSON & JOHNSON
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Hoffmann-La Roche AG
  • Sanofi S.A
  • Shire Plc.
  • Teva Pharmaceuticals Industries Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Carrier Type
  • Market Snippet, By Application
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Pipeline Analysis
• Reimbursement Scenario
• Epidemiology
• Pest Analysis
• Regulatory Scenario
• New Product Launches
• Collaborations and Agreements
• Market Trends

4. Global Nanopharmaceuticals Market, By Carrier Type, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Liposomes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Polymer
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Nanocrystals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Inorganic
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Protein
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

5. Global Nanopharmaceuticals Market, By Application, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Neurology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Anti-inflammatory
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Anti-infective
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Cardiovascular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

6. Global Nanopharmaceuticals Market, By Distribution Channel, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (USD Mn)

7. Global Nanopharmaceuticals Market, By Region, 2026 - 2033, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
• North America
  • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
• Middle East
  • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Carrier Type, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Application, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2026 - 2033, (USD Mn)
  • Market Size and Forecast, By Country, 2026 - 2033, (USD Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Abbott Laboratories
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • GlaxoSmithKline plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Astrazeneca plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Novavax, Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Stryker Corporation
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • OSI Pharmaceuticals
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Kadmon Pharmaceuticals
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Samyang Biopharm
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Mitsubishi Tanabe Pharma Corporation
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Kaken Pharmaceutical
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Selecta Biosciences
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Par Pharmaceutical
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Cerulean Pharma Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Navidea Biopharmaceuticals
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • AbbVie Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • AMAG Pharmaceuticals
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Amgen Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Astellas Pharma Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Celgene Corporation
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Gilead Sciences, Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • JOHNSON & JOHNSON
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Merck & Co., Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Novartis AG
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Pfizer, Inc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Hoffmann-La Roche AG
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Sanofi S.A
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Shire Plc.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Teva Pharmaceuticals Industries Limited.
    • Company Overview
    • Product Type Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Analyst Views

9. Section

• References
• Research Methodology
• About us and Sales Contact